In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line ...

President Trump’s threat to impose 30% tariffs on the European Union disrupted negotiations. From cars to wine, these are the ...

Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

In addition to obesity, modifiable risk factors include a low-quality diet (such as high consumption of processed meats, ...

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...